Compare Gilead Sciences, Inc. (GILD) vs Newmont Corporation (NEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Newmont Corporation — how do they compare? Gilead Sciences, Inc. trades at $135.98 (market cap $168.35B), while Newmont Corporation trades at $119.27 (market cap $123.50B). The key difference: Gilead Sciences, Inc. is the larger of the two by market cap, and Gilead Sciences, Inc. pays the higher dividend (2.42%). Which is the better fit depends on your goals.
| GILD | NEM | |
|---|---|---|
Market Cap | $168.35B | $123.50B |
Sector | Health | Basic Materials |
52-Week High | $155.80 | $131.95 |
52-Week Low | $110.56 | $67.38 |
Enterprise Value | $191.42B | $120.09B |
Dividend Yield | 2.42% | 0.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.06, down slightly by 0.11% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 revenue growth of 8% year-over-year, beating estimates, though a net loss of $6.75 per share resulted from acquisition-related costs. Analyst consensus is strongly bullish with a $151.22 price target, and recent news highlights robust HIV drug sales and pipeline progress.
The outlook for GILD is positive, driven by raised 2026 guidance and HIV franchise strength, but risks include patent cliffs by the mid-2030s and integration challenges from acquisitions. Investors should weigh the high valuation multiples against growth potential, with the stock offering upside if execution continues to exceed expectations.
Newmont Corporation (NEM) trades at $117.26, up 3.79% over 24 hours, near its 52-week high. The stock exhibits strong bullish technical signals and robust fundamentals, with revenue growing to $22.67 billion in 2025 and net income reaching $7.09 billion. Recent news highlights the resolution of a Nevada joint venture dispute with Barrick Mining, providing operational clarity.
The outlook for NEM remains positive, supported by strong earnings beats, a favorable analyst consensus, and rising gold prices. Key risks include gold price volatility and execution of production targets. The consensus price target of $133.00 suggests upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →
